Credo Technology Group vs. Marvell Technology: Which Stock Is a Better Buy in 2026?

Credo reported FY2026 revenue of nearly $1.3 billion, up approximately 205.7% year over year, and net income of about $472.3 million; guidance points to more than 85% revenue growth for the full year. Marvell generated approximately $8.2 billion in FY2026 revenue, up 42.1%, and about $2.7 billion in net income. The article favors Credo for its faster AI-connectivity growth, while highlighting its roughly 90% top-10 customer revenue concentration and Taiwan supply-chain exposure; Marvell offers greater scale but faces customer, debt, integration, and China sales restrictions risks.

Analysis

The key underwriting question is not AI demand, but how much of that demand converts into durable, non-substitutable supplier economics. CRDO’s concentrated design wins create upside convexity if deployments scale, but also give a small number of hyperscalers leverage over pricing, qualification and second-sourcing. A procurement shift or one delayed program could therefore hit growth and the multiple at once. SBC-adjusted cash generation is a useful check: track dilution and per-share FCF, not headline cash flow alone.

MRVL offers broader exposure to data infrastructure, but its cited distributor concentration should not be treated as equivalent to end-customer concentration; verify sell-through and end-market exposure before drawing that conclusion. Both companies remain exposed to AI-capex expectations, so a weaker hyperscaler spending outlook can overwhelm company-specific execution. TSM-linked supply-chain risk is a sector tail, not a CRDO-only differentiator absent evidence on each company’s sourcing and inventory.

Contrarian read: the article’s preference for CRDO leans heavily on recent growth, while its valuation comparison uses different reporting periods and unverified forward estimates. Similar sales multiples do not establish equal value when growth, durability and dilution differ. The near-term trade is therefore a relative execution call, not a clean valuation arbitrage. Over 1–3 months, prioritize reported customer concentration, design-win conversion, gross-margin direction and guidance; over 6–18 months, watch whether additional customers reduce the binary nature of CRDO’s growth. A thesis against CRDO is falsified by sustained growth accompanied by broader customer mix and stable per-share economics.

Key Decisions for Investors

• Do not chase CRDO solely on the article’s growth narrative. Before sizing, reconcile the cited fiscal periods and valuation inputs with current filings, and monitor customer concentration, dilution and per-share FCF.
• For a cautious relative-value expression, consider a modest, risk-weighted long MRVL / short CRDO position only after confirming current estimates and valuation spreads. The thesis is lower single-program exposure at MRVL, not that CRDO’s demand is weaker; cap the position because both are exposed to AI-capex sentiment.
• Prefer waiting for the next earnings and guidance cycle to add CRDO. A broader customer mix with sustained margins would support adding; a guidance cut, margin deterioration, or evidence of a delayed or displaced program would invalidate the bullish case.
• Track hyperscaler capex signals and TSM supply-chain developments as common-factor risks. If spending expectations deteriorate, reduce both exposures rather than assuming diversification between these two names provides a sufficient hedge.